Gene Network Sciences, UConn To Work On Computer-Modeled Ovarian Cancer Treatments

Gene Network Sciences, Inc. (GNS) today announced that it has entered into a research collaboration with The University of Connecticut Health Center’s Carole and Ray Neag Comprehensive Cancer Center in which the parties will incorporate genetic, genomic and clinical data (“3-D Data”) together into computer models of different cancers [with ovarian cancer as initial area of focus] to be used to identify the best treatments for individual patients and to develop new drug treatments and diagnostics.

Gene Network Sciences Announces Cancer Collaboration with University of Connecticut Health Center’s Neag Comprehensive Cancer Center

CAMBRIDGE, Mass., June 3 — Gene Network Sciences, Inc. (GNS) today announced that it has entered into a research collaboration with The University of Connecticut Health Center’s Carole and Ray Neag Comprehensive Cancer Center in which the parties will incorporate genetic, genomic and clinical data (“3-D Data”) together into computer models of different cancers to be used to identify the best treatments for individual patients and to develop new drug treatments and diagnostics. Financial terms were not disclosed.

runowicz

Carolyn D. Runowicz, M.D., Director, Neag Comprehensive Cancer Center, Univ. of Conn. Health Center; Chair, National Cancer Advisory Board

Tom Neyarapally, Senior VP, Corporate Development, Gene Network Sciences, Inc.

GNS and the Neag Comprehensive Cancer Center began their collaboration as a result of a connection made last year between two University of Connecticut alumni from different generations, Dr. Carolyn Runowicz (a graduate of the College of Liberal Arts and Sciences in the 1970s) and Tom Neyarapally (a graduate of the School of Engineering in the 1990s). Runowicz, who served as President of the American Cancer Society from 2005-2006 and is currently Director of the Neag Comprehensive Cancer Center, and Neyarapally identified ovarian cancer as an initial area of focus. Runowicz and Neyarapally are also, together with colleagues Drs. Molly Brewer and Iya Khalil, preparing a scientific publication regarding ovarian cancer treatment and the use of computational modeling capabilities such as GNS’s supercomputing-driven REFS(TM)[Reverse Engineering/Foward Simulation] platform to improve treatments and outcomes. The parties are also in the process of assembling a consortium in ovarian cancer with additional cancer centers that have yet to be named.

“With ever-increasing quantities of molecular and genetic data from cancer patients becoming available, we as clinicians are in great need of capabilities to optimally and rapidly utilize this information,” said Dr. Runowicz. “We are excited to link up with GNS, which has created a unique supercomputer-driven technology platform to turn this information directly into simulation models, and ultimately better treatments, for cancer patients.”

The parties will utilize the Neag Comprehensive Cancer Center’s clinical expertise to assess and validate findings from the ovarian cancer model simulations and will work with strategic partners to make drugs and diagnostics created based on these discoveries available to patients. They are also currently in discussions regarding the application of the REFS(TM) platform in other cancers such as prostate cancer.

“GNS is looking forward to working with the Neag Comprehensive Cancer Center’s extremely talented cancer researchers to rapidly convert data into actionable computer models of different cancers and clinical insights,” said Neyarapally, Senior Vice President of Corporate Development at GNS. “We feel privileged to be working closely with Dr. Runowicz, an established leader in the fight against cancer.”

About Gene Network Sciences

Gene Network Sciences (http://www.gnsbiotech.com/) is a leader in biosimulation with its ability to derive molecular mechanisms of drugs and diseases directly from molecular profiling and clinical data. Based in Cambridge, Massachusetts, and Ithaca, New York, GNS uses its REFS(TM) technology in pharmaceutical and clinical settings to rapidly turn combinations of genetic, genomic, and clinical measurements into models of disease progression and drug response. These models are then simulated to discover both new targets for drug intervention and genetic markers of drug response that allow patients who will respond to a given drug treatment to be matched to a particular clinical trial. By discovering how and why specific sets of genes and drug candidates impact human biology, GNS technology enables the rapid development of breakthrough drug and diagnostic products.

About The University of Connecticut Health Center

The University of Connecticut Health Center includes the schools of medicine and dental medicine, the UConn Medical Group, University Dentists, and John Dempsey Hospital. Founded in 1961, the Health Center pursues a mission of providing outstanding health care education in an environment of exemplary patient care, research and public service. To learn more about the UConn Health Center, visit our website at http://www.uchc.edu.

Contact:
Thomas Neyarapally
Gene Network Sciences
(617) 494-0492
tneyarapally@gnsbiotech.com

SourceGene Network Sciences announces a cancer collaboration with the University of Connecticut Health Center’s NEAG Comprehensive Cancer Center, Press Release, June 3, 2009.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s